Pfizer Inc. (NYSE: PFE) announced the Phase 2b results of a 24 week, randomized, placebo-controlled, dose-ranging study of investigational bococizumab ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE